- Home
- RXRX vs SLNO Comparison
RXRX vs SLNO Comparison
Compare RXRX & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXRX
- SLNO
- Stock Information
- Founded
- RXRX 2013
- SLNO 1999
- Country
- RXRX United States
- SLNO United States
- Employees
- RXRX N/A
- SLNO N/A
- Industry
- RXRX Biotechnology: Pharmaceutical Preparations
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- RXRX Health Care
- SLNO Health Care
- Exchange
- RXRX Nasdaq
- SLNO Nasdaq
- Market Cap
- RXRX 2.6B
- SLNO 2.2B
- IPO Year
- RXRX 2021
- SLNO 2014
- Fundamental
- Price
- RXRX $6.22
- SLNO $45.27
- Analyst Decision
- RXRX Buy
- SLNO Strong Buy
- Analyst Count
- RXRX 5
- SLNO 6
- Target Price
- RXRX $9.25
- SLNO $74.83
- AVG Volume (30 Days)
- RXRX 15.6M
- SLNO 720.3K
- Earning Date
- RXRX 11-06-2024
- SLNO 11-06-2024
- Dividend Yield
- RXRX N/A
- SLNO N/A
- EPS Growth
- RXRX N/A
- SLNO N/A
- EPS
- RXRX N/A
- SLNO N/A
- Revenue
- RXRX $65,184,000.00
- SLNO N/A
- Revenue This Year
- RXRX $60.17
- SLNO N/A
- Revenue Next Year
- RXRX $19.88
- SLNO N/A
- P/E Ratio
- RXRX N/A
- SLNO N/A
- Revenue Growth
- RXRX 37.64
- SLNO N/A
- 52 Week Low
- RXRX $5.60
- SLNO $35.70
- 52 Week High
- RXRX $15.74
- SLNO $60.92
- Technical
- Relative Strength Index (RSI)
- RXRX 43.38
- SLNO 32.32
- Support Level
- RXRX $6.75
- SLNO $45.00
- Resistance Level
- RXRX $7.85
- SLNO $48.77
- Average True Range (ATR)
- RXRX 0.79
- SLNO 2.24
- MACD
- RXRX -0.07
- SLNO -0.45
- Stochastic Oscillator
- RXRX 4.99
- SLNO 9.17
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.